Abstract
Background
17β-Estradiol (E2) is generally considered neuroprotective in humans. However, the current clinical use of estrogen replacement therapy (ERT) is based on the physiological dose of E2 to treat menopausal syndrome and has limited therapeutic efficacy. The efficacy and potential toxicity of superphysiological doses of ERT for menopausal neurodegeneration are unknown.
Methods
In this study, we investigated the effect of E2 with a supraphysiologic dose (0.5 mg/kg, sE2) on the treatment of menopausal mouse models established by ovariectomy. We performed the open field, Y-maze spontaneous alternation, forced swim tests, and sucrose preference test to investigate behavioral alterations. Subsequently, the status of microglia and neurons was detected by immunohistochemistry, HE staining, and Nissl staining, respectively. Real-time PCR was used to detect neuroinflammatory cytokines in the hippocampus and cerebral cortex. Using mass spectrometry proteomics platform and LC–MS/ MS-based metabolomics platform, proteins and metabolites in brain tissues were extracted and analyzed. BV2 and HT22 cell lines and primary neurons and microglia were used to explore the underlying molecular mechanisms in vitro.
Results
sE2 aggravated depression-like behavior in ovariectomized mice, caused microglia response, and increased proinflammatory cytokines in the cerebral cortex and hippocampus, as well as neuronal damage and glycerophospholipid metabolism imbalance. Subsequently, we demonstrated that sE2 induced the pro-inflammatory phenotype of microglia through ERα/NF-κB signaling pathway and downregulated the expression of cannabinoid receptor 1 in neuronal cells, which were important in the pathogenesis of depression.
Conclusion
These data suggest that sE2 may be nonhelpful or even detrimental to menopause-related depression, at least partly, by regulating microglial responses and glycerophospholipid metabolism.
Similar content being viewed by others
Introduction
The climacteric period is commonly known as menopause, marking the end of the reproductive period for most women [1]. With the increased social pressure and the accelerated pace of life, the incidence of menopausal depression in women tends to be high [2]. Generally, depression is a broad and heterogenous diagnosis, with depressed mood and/or loss of pleasure in activities as the main diagnostic characteristics [3].
Many studies have revealed that neuroinflammation, triggered by the activation of microglia, is closely related to the pathogenesis of depression [4]. Microglia are important immune cells in the central nervous system (CNS), playing an important role in the occurrence and development of depression [5]. Under normal physiological conditions, microglia are in a quiescent state, monitoring CNS homeostasis. In response to stresses or abnormal neuronal activities, the morphology and functions of microglia are rapidly changed, presenting an activated state. According to the “gliocentric theory,” stress-induced inflammation resulting from microglia activation may trigger a cascade of glial dysfunctions that supports the development of depressive disorders [6].
Evidence suggests that the endogenous cannabinoid system is involved in the pathophysiology of depression [7]. Endocannabinoids are signaling lipids that activate cannabinoid receptors in the CNS and peripheral tissues. Cannabinoid receptors are divided into two classes, i.e., cannabinoid receptor 1 (CB1) and cannabinoid receptor 2 (CB2). The CB1 receptors in the brain are mainly distributed in presynaptic axons and nerve endings [8]. Certain genetic polymorphisms in CB1 and CB2 receptors are associated with major depression and bipolar disorder, while the CB1 knockout mice showed significant depression-like behaviors [9, 10]. Besides, the selective estrogen receptor modulators (SERMs), e.g., tamoxifen, are used to treat estrogen receptor (ER)-positive breast cancer and osteoporosis. Interestingly, as indicated as a potential ER-independent target, tamoxifen binds to cannabinoid receptors (CBRs) with affinity in the low concentration range and acts as an inverse agonist [11]. Suggesting that the estrogen receptor activation could promote CBRs to undergo the relevant responses.
Many of the health complications associated with menopause in women are directly related to decreased functions of the ovarian hormone, primarily 17β-Estradiol (E2) deficiency. Therefore, the importance of physiological hormone replacement therapies, mainly including E2 replacement therapy (ERT), has attracted increasing attention in the treatment of postmenopausal women [12].
Currently, hormone therapy in menopausal syndrome is still controversial. Firstly, in animal and cell experiments, the ERT has shown anti-inflammatory and antioxidant effects, stabilizing intracellular calcium levels, modulating the cholinergic system, and ultimately improving cognitive functions and depressive-like behaviors in ovariectomized (OVX) mice [37]. Several laboratory and clinical studies have reported that E2 showed no effect on these diseases in elderly postmenopausal women but increased the risk of the onset and even mortality of the patients of these diseases [38].
Xu et al. conducted animal studies to demonstrate that the administration of E2 effectively ameliorated the depressive behaviors through the inhibition of inflammation and the activation of indoleamino-2, 3-dioxygenase (IDO), ultimately regulating the levels of 5-hydroxytryptamine (5-HT) in the hippocampus [39]. However, the evidence for estrogenic antidepressant-like effects in humans is less conclusive compared to rodent studies, and in some cases, contradictory findings have been reported [40]. Therefore, the effective physiological doses of E2 supplementation for menopausal depression are still controversial. In fact, several studies have explored the medical effects of sE2. For example, Bronwyn et al. found that sE2 impaired the preestrus fear resolution in rats [41]. While Stephanie et al. found that high doses of E2 could prevent heart failure after myocardial infarction in rats [42].
In our study, the results revealed the potentially neurotoxic effect of sE2. To investigate the therapeutic effect of sE2 on OVX mice, the sE2 (0.5 mg/kg) was intraperitoneally injected into the OVX mice for 5 weeks. The results showed that sE2 treatment worsened depressive-like behaviors in OVX mice. It is necessary to note that more explorations of the cerebrotoxic effects of different E2 doses and durations of action are needed in the future. Although this study used different concentrations and time gradients to detect the effects of E2 on neurons and microglia in vitro, the in vivo experiment was a single-endpoint (single-dose) test and could not accurately reflect the effects of E2 on the mouse brain in a wider time range and concentration gradient. Furthermore, it is imperative to investigate the direct impact of ERT on the brains of healthy mice that have not undergone ovariectomy, considering the adverse cardiovascular and cerebrovascular effects associated with ERT. Consequently, it is noted that this study is deficient in experiments involving the administration of sE2 to sham-operated mice. Therefore, it would be worthwhile to include mouse models of primary ovarian failure or normal menopausal experience as research subjects in future studies, as the menopausal women differ from OVX mice in their physiological conditions.
Previous research showed that the exogenous E2 supplementation was frequently employed as a prevalent therapeutic approach for managing climacteric syndrome by sustaining the peripheral blood levels of estrogen at physiological ranges [1]. Typically, three methods are employed to maintain the physiological estrogen level in animals, i.e., subcutaneous or intraperitoneal injection of estradiol, the implantation of sustained-release capsules containing estradiol beneath the neck or oral gavage. However, the actual dose used was varied in different studies to maintain the normal physiological levels of estrogen. For instance, Zhu et al. administered a dosage of 0.36 mg/60-day E2 to address the abdominal obesity in OVX mice, while Adachi et al. employed a dosage of 0.05 mg/21-day E2 to treat psoriatic inflammation in OVX mice [44, 45]. Zhou et al. administered a dose of 0.3 mg/kg/d E2 orally to mice to improve the cognitive decline and depressive behavior induced by OVX [46]. Consequently, we contend that the decision to employ E2 as a physiological dose should be based on standard serological assessments. Therefore, in our investigation, a dosage of E2 was administered to obtain a twofold increase in the concentration of E2 in the peripheral blood of mice, which exceeded the physiological range.
Recent research has shown that depressed patients exhibited lower cognitive abilities compared to people who were not depressed [47]. It is generally believed that depression precedes the development of cognitive deficits [48]. Notably, we found that although sE2 aggravated depressive-like behaviors in OVX mice, it did not affect their short-term memory based on the results of the Y-maze test. This observation could be explained from two perspectives. First, the pathogenetic causes of both memory deficits and depression were different, i.e., depression was not necessarily sufficient to impair the memory function of the brain [49]. Second, the brain damage caused by sE2 was not sufficient to affect the neuronal circuits responsible for memory [50, 51].
Furthermore, studies have shown that elevated E2 levels lead to decreased levels of follicle-stimulating hormone (FSH) due to negative feedback from the pituitary gland [52, 53]. Recent studies have shown that elevated FSH levels are an important factor in the development of Alzheimer's disease in menopausal women [66]. On the other hand, the high concentration of E2 could decrease the viability of primary neurons by inducing metabolic disorders, and HT22 cells themselves showed a strong regulatory ability to maintain the metabolic balance. In addition, in vitro models do not fully represent in vivo conditions. Therefore, further studies are still needed to confirm the security and the specific mechanisms in vivo of sE2.
Finally, the untargeted metabolomics results showed that the sE2 caused the imbalance of multiple metabolites involved in glycerophospholipid metabolism, retrograde endocannabinoid signaling, and so on, which are associated with depression. These results are consistent with the findings of Zhang et al. [6], showing that the long-term ERT treatment promotes CB1 ubiquitination in the brain of OVX mice, ultimately causing the fear extinction disorder [67]. Previous studies have shown that gut microbes induce depression by regulating glycerophospholipid metabolism, people with sleep deprivation and depression have abnormal glycerophospholipid metabolism, while abnormal glycerophospholipid metabolism also occurs in the brain of the depression rat model [68,69,70]. However, the molecular mechanisms regulating the participation of these metabolites in the above metabolic pathways remain unclear. Further studies are necessary to confirm whether the metabolic imbalance caused by sE2 is limited to neuronal cells, which also affects the metabolisms of microglia and astrocytes.
In conclusion, the sE2 induced depression in OVX mice in various ways, including the abnormal response of microglia and metabolic imbalance of neuronal cells. This study has revealed the potential risks and the underlying mechanisms of the application of sE2 in ERT in the treatment of menopausal depression.
Availability of data and materials
The data used and/or analyzed during the study are available from the corresponding author on reasonable request.
References
Kim GD, Chun H, Doo M. Associations among BMI, dietary macronutrient consumption, and climacteric symptoms in korean menopausal women. Nutrients. 2020;12(4):945. https://doi.org/10.3390/nu12040945.
Chu K, Shui J, Ma L, Huang Y, Wu F, Wei F, et al. Biopsychosocial risk factors of depression during the menopause transition in southeast China. BMC Womens Health. 2022;22(1):273. https://doi.org/10.1186/s12905-022-01710-4.
Perich T, Ussher J. Stress predicts depression symptoms for women living with bipolar disorder during the menopause transition. Menopause. 2021;29(2):231–5. https://doi.org/10.1097/GME.0000000000001894.
Slopien R, Pluchino N, Warenik-Szymankiewicz A, Sajdak S, Luisi M, Drakopoulos P, Genazzani A. Correlation between allopregnanolone levels and depressive symptoms during late menopausal transition and early postmenopause. Gynecol Endocrinol. 2018;34(2):144–7. https://doi.org/10.1080/09513590.2017.1371129.
Han QQ, Shen SY, Chen XR, Pilot A, Liang LF, Zhang JR, et al. Minocycline alleviates abnormal microglial phagocytosis of synapses in a mouse model of depression. Neuropharmacology. 2022;220:109249. https://doi.org/10.1016/j.neuropharm.2022.109249.
Wang H, He Y, Sun Z, Ren S, Liu M, Wang G, et al. Microglia in depression: an overview of microglia in the pathogenesis and treatment of depression. J Neuroinflammation. 2022;19(1):132. https://doi.org/10.1186/s12974-022-02492-0.
Leo LM, Abood ME. CB1 cannabinoid receptor signaling and biased signaling. Molecules. 2021;26(17):5413. https://doi.org/10.3390/molecules26175413.
Ye L, Cao Z, Wang W, Zhou N. New insights in cannabinoid receptor structure and signaling. Curr Mol Pharmacol. 2019;12(3):239–48. https://doi.org/10.2174/1874467212666190215112036.
Monteleone P, Bifulco M, Maina G, Tortorella A, Gazzerro P, Proto MC, Di Filippo C, Monteleone F, Canestrelli B, Buonerba G. Investigation of CNR1 and FAAH endocannabinoid gene polymorphisms in bipolar disorder and major depression. Pharmacol Res. 2010;61:400–4. https://doi.org/10.1016/j.phrs.2010.01.002.
Valverde O, Torrens M. CB1 receptor-deficient mice as a model for depression. Neuroscience. 2021;204:193–206. https://doi.org/10.1016/j.neuroscience.2011.09.031.
Franks LN, Ford BM, Prather PL. Selective estrogen receptor modulators: cannabinoid receptor inverse agonists with differential CB1 and CB2 selectivity. Front Pharmacol. 2016;7:503. https://doi.org/10.3389/fphar.2016.00503.
Sullivan SD, Sarrel PM, Nelson LM. Hormone replacement therapy in young women with primary ovarian insufficiency and early menopause. Fertil Steril. 2016;106(7):1588–99. https://doi.org/10.1016/j.fertnstert.2016.09.046.
He Q, Luo Y, Lv F, **ao Q, Chao F, Qiu X. Effects of 17β-Estradiol replacement therapy on the myelin sheath ultrastructure of myelinated fibers in the white matter of middle-aged ovariectomized rats. J Comp Neurol. 2018;526(5):790–802. https://doi.org/10.1002/cne.24366.
Almeida OP, Lautenschlager NT, Vasikaran S, Leedman P, Gelavis A, Flicker L. A 20-week randomized controlled trial of estradiol replacement therapy for women aged 70 years and older: effect on mood, cognition and quality of life. Neurobiol Aging. 2006;27(1):141–9. https://doi.org/10.1016/j.neurobiolaging.2004.12.012.
Zhao Y, Che J, Tian A, Zhang G, Xu Y, Li S. PBX1 participates in 17β-estradiol-mediated bladder cancer progression and chemo-resistance affecting estrogen receptors. Curr Cancer Drug Targets. 2022;22(9):757–70. https://doi.org/10.2174/1568009622666220413084456.
Babiloni-Chust I, Dos Santos RS, Medina-Gali RM, Perez-Serna AA, Encinar JA, Martinez-Pinna J. G protein-coupled estrogen receptor activation by bisphenol-A disrupts the protection from apoptosis conferred by the estrogen receptors ERα and ERβ in pancreatic beta cells. Environ Int. 2022;164:107250. https://doi.org/10.1016/j.envint.2022.107250.
Khan MZI, Uzair M, Nazli A, Chen JZ. An overview on estrogen receptors signaling and its ligands in breast cancer. Eur J Med Chem. 2022;41:114658. https://doi.org/10.1016/j.ejmech.2022.114658.
Hall JM, Couse JF, Korach KS. The multifaceted mechanisms of estradiol and estrogen receptor signaling. J Biol Chem. 2001;276(40):36869–72. https://doi.org/10.1074/jbc.R100029200.
Maximov PY, Abderrahman B, Fanning SW, Sengupta S, Fan P, Curpan RF. Endoxifen, 4-hydroxytamoxifen and an 17β-estradiolic derivative modulate estrogen receptor complex mediated apoptosis in breast cancer. Mol Pharmacol. 2018;94(2):812–22. https://doi.org/10.1124/mol.117.111385.
McCombe PA, Greer JM, Mackay IR. Sexual dimorphism in autoimmune disease. Curr Mol Med. 2009;9(9):1058–79. https://doi.org/10.2174/156652409789839116.
Gresack JE, Frick KM. Post-training 17β-Estradiol enhances spatial and object memory consolidation in female mice. Pharmacol Biochem Behav. 2006;84(1):112–9. https://doi.org/10.1016/j.pbb.2006.
Jung Koo H, Sohn EH, Kim YJ, Jang SA, Namkoong S, Chan KS. Effect of the combinatory mixture of Rubus coreanus Miquel and Astragalus membranaceus Bunge extracts on ovariectomy-induced osteoporosis in mice and anti-RANK signaling effect. J Ethnopharmacol. 2014;151(2):951–9. https://doi.org/10.1016/j.jep.2013.12.008.
Meng L, Zou L, **ong M, Chen J, Zhang X, Yu T. A synapsin I cleavage fragment contributes to synaptic dysfunction in Alzheimer’s disease. Aging Cell. 2022;21(5):e13619. https://doi.org/10.1111/acel.13619.
**ao W, Li J, Gao X, Yang H, Su J, Weng R. Involvement of the gut-brain axis in vascular depression via tryptophan metabolism: a benefit of short chain fatty acids. Exp Neurol. 2022;358:114225. https://doi.org/10.1016/j.expneurol.2022.114225.
Mirakhur M, Diener M. Proteinase-activated receptors regulate intestinal functions in a segment-dependent manner in rats. Eur J Pharmacol. 2022;933:175264. https://doi.org/10.1016/j.ejphar.2022.175264.
Ettinger RA, James EA, Kwok WW, Thompson AR, Pratt KP. Lineages of human T-cell clones, including T helper 17/T helper 1 cells, isolated at different stages of anti-factor VIII immune responses. Blood. 2009;114(7):1423–8. https://doi.org/10.1182/blood-2009-01-200725.
Karnovsky A, Li S. Pathway analysis for targeted and untargeted metabolomics. Methods Mol Biol. 2020;2104:387–400. https://doi.org/10.1007/978-1-0716-0239-319.
Kim J, Choi H, Kang EK, Ji GY, Kim Y, Choi IS. In vitro studies on therapeutic effects of cannabidiol in neural cells: neurons, glia, and neural stem cells. Molecules. 2021;26(19):6077. https://doi.org/10.3390/molecules26196077.
Mancinelli S, Turcato A, Kisslinger A, Bongiovanni A, Zazzu V, Lanati A. Design of transfections: implementation of design of experiments for cell transfection fine tuning. Biotechnol Bioeng. 2021;118(11):4488–502. https://doi.org/10.1002/bit.27918.
Taylor SC, Posch A. The design of a quantitative western blot experiment. Biomed Res. 2014. https://doi.org/10.1155/2014/361590.
Zuena AR, Mairesse J, Casolini P, Cinque C, Alemà GS, Morley-Fletcher S. Prenatal restraint stress generates two distinct behavioral and neurochemical profiles in male and female rats. PLoS ONE. 2008;3(5):e2170. https://doi.org/10.1371/journal.pone.0002170.
Zhou Z, Bachstetter AD, Späni CB, Roy SM, Watterson DM, Van Eldik LJ. Retention of normal glia function by an isoform-selective protein kinase inhibitor drug candidate that modulates cytokine production and cognitive outcomes. J Neuroinflammation. 2017;14(1):75. https://doi.org/10.1186/s12974-017-0845-2.
Liu Y, Zhang S, Li X, Liu E, Wang X, Zhou Q. Peripheral inflammation promotes brain tau transmission via disrupting blood-brain barrier. Biosci Rep. 2021;40(2):BSR20193629.
Ko SH, Jung Y. Energy metabolism changes and dysregulated lipid metabolism in postmenopausal women. Nutrients. 2021;13(12):4556. https://doi.org/10.1042/BSR20193629.
Hashimoto K, Malchow B, Falkai P, Schmitt A. Glutamate modulators as potential therapeutic drugs in schizophrenia and affective disorders. Eur Arch Psychiatry Clin Neurosci. 2013;263(5):367–77. https://doi.org/10.1007/s00406-013-0399-y.
Rani A, Stebbing J, Giamas G, Murphy J. Endocrine resistance in hormone receptor positive breast cancer-from mechanism to therapy. Front Endocrinol (Lausanne). 2019;10:245. https://doi.org/10.3389/fendo.2019.00245.\.
Guo H, Liu M, Zhang L, Wang L, Hou W, Ma Y. The critical period for neuroprotection by 17β-estradiol replacement therapy and the potential underlying mechanisms. Curr Neuropharmacol. 2020;18(6):485–500. https://doi.org/10.2174/1570159X18666200123165652.
Li Y, Zhang X, Xu S, Ge J, Liu J, Li L. Expression and clinical significance of FXYD3 in endometrial cancer. Oncol Lett. 2014;8(2):517–22. https://doi.org/10.3892/ol.2014.2170.
Xu Y, Sheng H, Tang Z, Lu J, Ni X. Inflammation and increased IDO in hippocampus contribute to depression-like behavior induced by estrogen deficiency. Behav Brain Res. 2015;288:71–8. https://doi.org/10.1016/j.bbr.2015.04.017.
Kuehner C. Why is depression more common among women than among men? Lancet Psychiatry. 2017;4(2):146–58. https://doi.org/10.1016/S2215-0366(16)30263-2.
Graham BM, Scott E. Effects of systemic estradiol on fear extinction in female rats are dependent on interactions between dose, estrous phase, and endogenous estradiol levels. Horm Behav. 2018;97:67–74. https://doi.org/10.1016/j.yhbeh.2017.10.009.
Beer S, Reincke M, Kral M, Callies F, Strömer H, Dienesch C. High-dose 17beta-estradiol treatment prevents development of heart failure post-myocardial infarction in the rat. Basic Res Cardiol. 2007;102(1):9–18. https://doi.org/10.1007/s00395-006-0608-1.
Yan H, Yang W, Zhou F, et al. Estrogen improves insulin sensitivity and suppresses gluconeogenesis via the transcription factor Foxo1. Diabetes. 2019;68(2):291–304. https://doi.org/10.2337/db18-0638.
Zhu J, Zhang L, Ji M, ** B, Shu J. Elevated adipose differentiation-related protein level in ovariectomized mice correlates with tissue-specific regulation of estrogen. J Obstet Gynaecol Res. 2023;49(4):1173–9. https://doi.org/10.1111/jog.15565.
Adachi A, Honda T, Egawa G, et al. Estradiol suppresses psoriatic inflammation in mice by regulating neutrophil and macrophage functions. J Allergy Clin Immunol. 2022;150(4):909-919.e8. https://doi.org/10.1016/j.jaci.2022.03.028.
Zhou XD, Shi DD, Wang HN, Tan QR, Zhang ZJ. Aqueous extract of lily bulb ameliorates menopause-like behavior in ovariectomized mice with novel brain-uterus mechanisms distinct from estrogen therapy. Biomed Pharmacother. 2019;117:109114. https://doi.org/10.1016/j.biopha.2019.109114.
Krolick KN, Zhu Q, Shi H. Effects of estrogens on central nervous system neurotransmission: implications for sex differences in mental disorders. Prog Mol Biol Transl Sci. 2018;160:105–71. https://doi.org/10.1016/bs.pmbts.2018.07.008.
Lai S, Zhong S, Wang Y, Zhang Y, Xue Y, Zhao H. The prevalence and characteristics of MCCB cognitive impairment in unmedicated patients with bipolar II depression and major depressive disorder. J Affect Disord. 2022;310:369–76. https://doi.org/10.1016/j.jad.2022.04.153.
Kassel MT, Rhodes E, Insel PS, Woodworth K, Garrison-Diehn C, Satre DD, Nelson JC, Tosun D, Mackin RS. Cognitive outcomes are differentially associated with depression severity trajectories during psychotherapy treatment for late life major depressive disorder. Int J Geriatr Psychiatry. 2022. https://doi.org/10.1002/gps.5779.
Bisol Balardin J, Vedana G, Ludwig A, de Lima DB, Argimon I, Schneider R. Contextual memory and encoding strategies in young and older adults with and without depressive symptoms. Aging Ment Health. 2009;13(3):313–8. https://doi.org/10.1080/13607860802534583.
Ponsoni A, Damiani Branco L, Cotrena C, Milman Shansis F, Fonseca RP. The effects of cognitive reserve and depressive symptoms on cognitive performance in major depression and bipolar disorder. J Affect Disord. 2020;274:813–8. https://doi.org/10.1016/j.jad.2020.05.143.
Subramaniapillai M, Mansur RB, Zuckerman H, Park C, Lee Y, Iacobucci M. Association between cognitive function and performance on effort based decision making in patients with major depressive disorder treated with Vortioxetine. Compr Psychiatry. 2019;94:152113. https://doi.org/10.1016/j.comppsych.2019.07.006.
Gong Z, Shen X, Yang J, Lai L, Wei S. Receptor binding inhibitor suppresses carcinogenesis of cervical cancer by depressing levels of FSHR and ERβ in mice. Anticancer Agents Med Chem. 2019;19(14):1719–27. https://doi.org/10.2174/1871520619666190801094059.
Wang N, Si C, **a L, Wu X, Zhao S, Xu H. TRIB3 regulates FSHR expression in human granulosa cells under high levels of free fatty acids. Reprod Biol Endocrinol. 2021;19(1):139. https://doi.org/10.1186/s12958-021-00823-z.
**ong J, Kang SS, Wang Z, Liu X, Kuo TC, Korkmaz F. FSH blockade improves cognition in mice with Alzheimer’s disease. Nature. 2022;603(7901):470–6. https://doi.org/10.1038/s41586-022-04463-0.
Bi WK, Shao SS, Li ZW, Ruan YW, Luan SS, Dong ZH. FSHR ablation induces depression-like behaviors. Acta Pharmacol Sin. 2020;41(8):1033–40. https://doi.org/10.1038/s41401-020-0384-8.
Bi WK, Luan SS, Wang J, Wu SS, ** XC, Fu YL. FSH signaling is involved in affective disorders. Biochem Biophys Res Commun. 2020;525(4):915–20. https://doi.org/10.1016/j.bbrc.2020.03.039.
Meng X, Huang X, Deng W, Li J, Li T. Serum uric acid a depression biomarker. PLoS ONE. 2020;15(3):e0229626. https://doi.org/10.1371/journal.pone.0229626.
Xu Y, Sheng H, Bao Q, Wang Y, Lu J, Ni X. NLRP3 inflammasome activation mediates estrogen deficiency-induced depression- and anxiety-like behavior and hippocampal inflammation in mice. Brain Behav Immun. 2016;56:175–86. https://doi.org/10.1016/j.bbi.2016.02.022.
Picard K, Bisht K, Poggini S, Garofalo S, Golia MT, Basilico B. Microglial-glucocorticoid receptor depletion alters the response of hippocampal microglia and neurons in a chronic unpredictable mild stress paradigm in female mice. Brain Behav Immun. 2021;97:423–39. https://doi.org/10.1016/j.bbi.2021.07.022.
Lolier M, Wagner CK. Sex differences in dopamine innervation and microglia are altered by synthetic progestin in neonatal medial prefrontal cortex. J Neuroendocrinol. 2021;33(3):e12962. https://doi.org/10.1111/jne.12962.
Ma Y, Niu E, **e F, Liu M, Sun M, Peng Y. Electroacupuncture reactivates estrogen receptors to restore the neuroprotective effect of estrogen against cerebral ischemic stroke in long-term ovariectomized rats. Brain Behav. 2021;11(10):e2316. https://doi.org/10.1002/brb3.2316.
Burguete MC, Jover-Mengual T, López-Morales MA, Aliena-Valero A, Jorques M, Torregrosa G. The selective oestrogen receptor modulator, bazedoxifene, mimics the neuroprotective effect of 17β-oestradiol in diabetic ischaemic stroke by modulating oestrogen receptor expression and the MAPK/ERK1/2 signalling pathway. J Neuroendocrinol. 2019;31(8):e12751. https://doi.org/10.1111/jne.12751.
Yang S, Magnutzki A, Alami NO, Lattke M, Hein TM, Scheller JS. IKK2/NF-κB activation in astrocytes reduces amyloid β deposition: a process associated with specific microglia polarization. Cells. 2021;10(10):2669. https://doi.org/10.3390/cells10102669.
Fleischer AW, Schalk JC, Wetzel EA, et al. Long-term oral administration of a novel estrogen receptor beta agonist enhances memory and alleviates drug-induced vasodilation in young ovariectomized mice. Horm Behav. 2021;130:104948. https://doi.org/10.1016/j.yhbeh.2021.104948.
Ginhoux F, Lim S, Hoeffel G, Low D, Huber T. Origin and differentiation of microglia. Front Cell Neurosci. 2013;7:45. https://doi.org/10.3389/fncel.2013.00045.
Zhang K, Yang Q, Yang L, et al. CB1 agonism prolongs therapeutic window for hormone replacement in ovariectomized mice. J Clin Invest. 2019;129(6):2333–50. https://doi.org/10.1172/JCI123689.
Zheng P, Wu J, Zhang H, Perry SW, Yin B, Tan X, et al. The gut microbiome modulates gut-brain axis glycerophospholipid metabolism in a region-specific manner in a nonhuman primate model of depression. Mol Psychiatry. 2021;26(6):2380–92. https://doi.org/10.1038/s41380-020-0744-2.
Tian T, Mao Q, **e J, Wang Y, Shao WH, Zhong Q. Multi-omics data reveals the disturbance of glycerophospholipid metabolism caused by disordered gut microbiota in depressed mice. J Adv Res. 2022;39:135–45. https://doi.org/10.1016/j.jare.2021.10.002.
Davies SK, Ang JE, Revell VL, Holmes B, Mann A, Robertson FP. Effect of sleep deprivation on the human metabolome. Proc Natl Acad Sci U S A. 2014;111(29):10761–6. https://doi.org/10.1073/pnas.1402663111.
Funding
This work was supported by The National Key Research and Development Program of China (2017YFC1001002).
Author information
Authors and Affiliations
Contributions
ML and JZ accomplished most of the experiments, analyzed the results, and wrote the manuscript. YZ designed this study. WC, SL, LX, YN and YC took part in various aspects of the study and read and revised first draft. All authors read and approved the final manuscript.
Corresponding author
Ethics declarations
Ethics approval and consent to participate
All animal experiments followed the ethical standards for laboratory animals approved by the Ethics Committee of the Reproductive Hospital Affiliated with Shandong University (No. 21172).
Competing interests
The authors declare no competing interests.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary Information
Additional file 1: Figure S1.
Exogenous estrogen supplementation significantly increased peripheral blood estrogen levels in ovariectomized mice. (A) A Schematic illustration of the workflow of animal experiments. (B) Serum 17β-Estradiol levels in all groups of mice. Students t-test is performed to determine the significant difference based on P < 0.05 (*), P < 0.01 (**), and P < 0.001 (***), respectively, in comparison to the sham group (as indicated by black asterisks and “ns”). ns: not significant difference. Data are presented as mean ± the standard deviation (SD) of at least four animals per group.
Additional file 2: Figure S2.
Cannabinoid receptor 1 (CB1) inhibited by hE2/sE2 in primary neuron cells and OVX mouse brain. (A) Primary neuron cells fixed and immunostained for CB1 (red). Bar = 30 µm. Cells are incubated with E2 of 0 nmol/L to 3200 nmol/L for 24 h. (B) Mean fluorescence intensity of CB1 expressed as a relative change in comparison with untreated cells. (C) The mRNA levels of CB1 in primary neurons treated with E2 of different concentrations. (D) RNA levels of CB1 in hippocampus and cortex of mice in each group. Students t-test is performed to determine the significant difference based on P < 0.05 (*), P < 0.01 (**), and P < 0.001 (***), respectively, in comparison to the sham or control groups as indicated by black asterisks or “ns” and to the OVX group as indicated by red asterisks. ns: no significant difference. Data are presented as mean ± standard deviation (SD). Each experiments is repeated independently twice. Data are based on a minimum of 10 animals in each group.
Additional file 3: Figure S3.
Analysis of non‐targeted metabolomics of brains from sE2‐treated OVX mice compared to vehicle‐treated OVX mice under negative ions. (A) Heatmap of 48 significantly changed metabolites based on untargeted metabolomics. (B) KEGG enrichment analysis of the differential metabolites. The X-axis indicates the number of annotated metabolites under a certain pathway as a percentage of all annotated metabolites. (C) Matchstick analysis of the differential metabolites. Red boxes indicate metabolites related to glycerophospholipid metabolism and retrograde endocannabinoid signaling. ANOVA is performed to determine the significant difference based on P < 0.05 (*), P < 0.01 (**), and P < 0.001 (***), respectively. (D) Pathway enrichment of differential metabolites. (E) Network analysis of the differential metabolites. (F) Heatmap of correlation analysis of differential metabolites. Each group contains a total of 5 animals.
Additional file 4: Table S1.
Primers and their sequences used for the quantitative real time PCR. Table S2. Primers and their sequences of siRNA duplexes for gene knockdown experiments.
Additional file 5:
Original western blots.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
About this article
Cite this article
Li, M., Zhang, J., Chen, W. et al. Supraphysiologic doses of 17β-estradiol aggravate depression-like behaviors in ovariectomized mice possibly via regulating microglial responses and brain glycerophospholipid metabolism. J Neuroinflammation 20, 204 (2023). https://doi.org/10.1186/s12974-023-02889-5
Received:
Accepted:
Published:
DOI: https://doi.org/10.1186/s12974-023-02889-5